Drug Interactions of Tipranavir, a New HIV Protease Inhibitor

Author(s): Judit Morello, Sonia Rodriguez-Novoa, Inmaculada Jimenez-Nacher, Vincent Soriano

Journal Name: Drug Metabolism Letters

Volume 1 , Issue 1 , 2007

Become EABM
Become Reviewer
Call for Editor


Tipranavir is one of the latest approved HIV protease inhibitors. This non-peptidic molecule is an strong inducer of cytochrome P450 and has to be co-administered with low doses ritonavir as pharmacokinetic booster to achieve effective antiviral activity in vivo. As expected, significant drug interactions may occur in patients treated with tipranavir/ ritonavir, including diminished exposure to some antiretroviral agents. Although a few interactions can be managed with adequate drug dosing others preclude to use these medications in combination.

Keywords: Tipranavir, HIV, drug interactions, protease inhibitors

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [81 - 84]
Pages: 4
DOI: 10.2174/187231207779814256

Article Metrics

PDF: 24